TherapeutAix has added contract research organizations (CROs), Alderley Analytical and Peak Proteins to its global R&D network, forming a dedicated team to address Pharmacokinetics and Pharmacodynamics (PK/PD) challenges for clients.

Based in Aachen, Germany, TherapeutAix is a biotech consultancy providing services from strategic planning to operationalization of studies. TherapeutAix has experience across multiple therapeutic areas, along with an integrated R&D network.

TherapeutAix has joined with Alderley Analytical, which provides specialist bioanalytical services to support drug development programs, and Peak Proteins, which offers protein expression and purification, protein crystallography, and protein mass spectrometry.

The dedicated project team will support TherapeutAix clients in overcoming challenging PK/PD situations.

The two Alderley Park-based CROs are the latest companies to join TherapeutAix’s R&D network, which also includes Apconix, Boyds, Immunoconsulting Ltd, Nordic Bioscience, OracleBio, and XenoGesis.

Bob Humphries, Director of Project Strategy at TherapeutAix, said, “One of the biggest challenges in drug discovery and development is understanding the bioavailability of a compound or drug and how it will behave in the body. Bringing this network of expertise together can help us to support clients with this challenge at an early stage, saving time and increasing the chances of a drug’s success.”